Res Eleni, Kyvelou Stella Maria, Vlachopoulos Charalambos, Manousou Kyriaki, Tousoulis Dimitris, Stefanadis Christodoulos, Pektasides Dimitris
Third Department of Medical Oncology, Agioi Anargyroi General Oncology Hospital of Kifissia.
Cardiology Department, First Cardiology Clinic, Athens Medical School, Hippokration Hospital,
Onco Targets Ther. 2018 Oct 11;11:6785-6793. doi: 10.2147/OTT.S156318. eCollection 2018.
The aim of the prospective study was to evaluate blood pressure (BP) and the arterial stiffness before and after chemotherapy in three subgroups of patients with metastatic colorectal, renal cell, and gastrointestinal carcinoma and exploit, if possible, the effect of chemotherapy and biological agents in the event of cardiotoxicity.
A total of 171 patients were included in the study: 60 with kidney cancer, 18 with gastrointestinal stromal tumors (GISTs), and 93 with metastatic colorectal cancer. All patients were subjected to full clinical and laboratory evaluation before and after chemotherapy. Arterial-stiffness indices were assessed before the initiation and after the completion of chemotherapy by means of pulse wave velocity (PWV; Complior) and augmentation index (AIx; SphygmoCor).
Patients in all three cancer cohorts exhibited significantly (<0.001) higher levels of carotid-radial PWV, carotid-femoral PWV, and AIx postchemotherapy, which remained significant after adjustment for BP and body-mass index. AIx exhibited greater change in the bowel-cancer cohort compared to the kidney and GIST cohorts (median 3.6, 1.75, and 1.4, respectively; <0.001), which remained significant after adjustment for BP and body-mass index. Multiple regression analysis showed that patients with higher baseline systolic BP, diastolic BP, ejection fraction, and carotid-femoral PWV exhibited smaller differences postchemotherapy, while AIx75 baseline levels showed no difference postchemotherapy.
There is a clear burden in arterial stiffness in patients under chemotherapy for kidney, GIST, and metastatic colorectal cancer, irrespective of BP and other confounders.
这项前瞻性研究的目的是评估转移性结直肠癌、肾细胞癌和胃肠道癌三个亚组患者化疗前后的血压(BP)和动脉僵硬度,并在可能的情况下探讨化疗和生物制剂对心脏毒性的影响。
共有171例患者纳入本研究:60例肾癌患者、18例胃肠道间质瘤(GIST)患者和93例转移性结直肠癌患者。所有患者在化疗前后均接受全面的临床和实验室评估。在化疗开始前和结束后,通过脉搏波速度(PWV;Complior)和增强指数(AIx;SphygmoCor)评估动脉僵硬度指数。
所有三个癌症队列的患者化疗后颈动脉-桡动脉PWV、颈动脉-股动脉PWV和AIx水平均显著升高(<0.001),在调整血压和体重指数后仍具有显著性。与肾癌和GIST队列相比,AIx在肠癌队列中的变化更大(中位数分别为3.6、1.75和1.4;<0.001),在调整血压和体重指数后仍具有显著性。多元回归分析显示,基线收缩压、舒张压、射血分数和颈动脉-股动脉PWV较高的患者化疗后差异较小,而AIx75基线水平化疗后无差异。
对于肾癌、GIST和转移性结直肠癌患者,无论血压和其他混杂因素如何,化疗都会导致明显的动脉僵硬度增加。